NFE2L2 and non-small cell lung carcinoma: The KEAPSAKE trial [NCT04265534] is a randomized phase 2 study evaluating telaglenastat + pembrolizumab + chemotherapy versus placebo as first-line treatment for stage IV non-squamous NSCLC with KEAP1/NRF2 mutation, with progression-free survival (PFS) and safety as the primary endpoints [84], but it was terminated before its contemplated completion date because of the lack of clinical benefit.